8-K: Neurogene Inc. Amends Consulting Agreement with Chief Scientific Officer

Neurogene Inc. has amended its consulting agreement with Stuart Cobb, Ph.D., its Chief Scientific Officer, outlining new terms for compensation and termination.

Summary

• Neurogene Inc. has entered into an amended and restated consulting agreement with Stuart Cobb Consulting Ltd., which relates to the services of Dr. Stuart Cobb as Chief Scientific Officer.
• The agreement, effective April 19, 2024, replaces the previous agreement from December 12, 2018.
• Dr. Cobb will receive a minimum annual consulting fee of $440,000, paid in monthly installments, with potential increases determined by the Board of Directors.
• He is also eligible for an annual success fee of up to 40% of his annual consulting fee, based on performance parameters set by the Board and his continued engagement with the company.
• In the event of termination without cause or resignation for good reason, Dr. Cobb is entitled to a lump sum payment equal to his annual consulting fee, any unpaid success fee from the previous year, and a pro-rata success fee for the current year.
• If termination occurs within three months before or twelve months after a change in control, Dr. Cobb will receive a lump sum payment equal to his annual consulting fee, a pro-rata bonus based on the target success fee, any unpaid success fee from the previous year, and accelerated vesting of his equity awards.

Sentiment

Score: 7

Explanation: The document is a routine update to an executive's consulting agreement, with no significant positive or negative implications. The terms are standard for the industry, and the agreement provides clarity on compensation and termination.

Positives

• The amended agreement provides clarity on the compensation and termination terms for the Chief Scientific Officer.
• The potential for a success fee of up to 40% incentivizes performance and continued engagement.
• The agreement includes provisions for payments and accelerated vesting of equity awards in the event of termination without cause or resignation for good reason, providing security for Dr. Cobb.

Risks

• The success fee is dependent on the Board's assessment of performance and continued engagement, which could be subjective.
• The termination clauses could result in significant payouts if Dr. Cobb is terminated without cause or resigns for good reason, especially around a change in control.

Future Outlook

The agreement outlines the terms of engagement for the Chief Scientific Officer, providing a framework for his continued service to the company.

Industry Context

This type of agreement is common for executive-level positions in biotech companies, ensuring that key personnel are incentivized and have clear terms of engagement.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include a base salary, performance-based bonuses, and equity awards.
• The structure of this agreement, with a base consulting fee and a potential success fee, is consistent with industry norms for Chief Scientific Officers.
• Termination clauses, including payments and accelerated vesting of equity, are also standard practice to protect both the company and the executive.
• Comparable companies such as BioMarin Pharmaceutical and Sarepta Therapeutics also have similar compensation structures for their executive teams.

Stakeholder Impact

• Shareholders will be interested in the compensation structure for key executives.
• Employees may be interested in the terms of engagement for the Chief Scientific Officer.
• The agreement provides clarity for the company and the executive, which can contribute to stability.

Next Steps

• The Restated Consulting Agreement will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023.

Key Dates

Keywords

consulting agreement, chief scientific officer, compensation, success fee, termination, equity awards, Neurogene Inc., Stuart Cobb